Orchestra BioMed (OBIO) director adds 5,000 shares in open-market buy

Rhea-AI Filing Summary

Orchestra BioMed Holdings, Inc. director and officer David P. Hochman reported an open-market purchase of 5,000 shares of Common Stock on June 1, 2026 at a weighted average price of $3.83 per share. After this transaction, he directly holds 1,064,029 shares of Common Stock.

Additional shares are held indirectly through various family trusts, including 439,482 shares held by the DPH 2008 Trust and smaller positions held by several 2008 and 2019 family trusts.

Insider Trade Summary

Net Buyer: 5,000 shares ($19,150)

Net Buy 6 txns

Insider Hochman David P

Role See Remarks

Bought 5,000 shs ($19K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share ("Common Stock")	5,000	$3.83	$19K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock, par value $0.0001 per share ("Common Stock") — 1,064,029 shares (Direct, null); Common Stock — 439,482 shares (Indirect, By the DPH 2008 Trust)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 5,000 shares Purchase price: $3.83 per share Direct holdings after trade: 1,064,029 shares +5 more

8 metrics

Shares purchased 5,000 shares Open-market purchase on June 1, 2026

Purchase price $3.83 per share Weighted average price, trades between $3.80 and $3.91

Direct holdings after trade 1,064,029 shares Common Stock directly held after June 1, 2026 purchase

DPH 2008 Trust holdings 439,482 shares Indirect ownership via DPH 2008 Trust

NSH 2008 Family Trust holdings 3,140 shares Indirect ownership via NSH 2008 Family Trust

Judah Herman Hochman 2019 Trust 2,000 shares Indirect ownership via 2019 trust

Hannah Hochman 2019 Trust 2,000 shares Indirect ownership via 2019 trust

Solomon Ascher Hochman 2019 Trust 2,000 shares Indirect ownership via 2019 trust

Key Terms

open-market purchase, weighted average price, indirect ownership, family trust

4 terms

open-market purchase financial

"Transaction action is described as an open-market purchase of Common Stock."

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported is a weighted average price for multiple trades."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirect ownership financial

"Several entries list indirect ownership through various family trusts."

family trust financial

"Holdings are attributed to the NSH 2008 Family Trust and 2019 trusts."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hochman David P

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PENNSYLVANIA 18938

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	06/01/2026		P		5,000	A	$3.83(1)	1,064,029	D
Common Stock								439,482	I	By the DPH 2008 Trust
Common Stock								2,000	I	By the Solomon Ascher Hochman 2019 Trust
Common Stock								2,000	I	By the Hannah Hochman 2019 Trust
Common Stock								2,000	I	By the Judah Herman Hochman 2019 Trust
Common Stock								3,140	I	By the NSH 2008 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.80 to $3.91. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Chief Executive Officer and Chairperson

	/s/ Andrew Taylor, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did OBIO report for David P. Hochman?

Orchestra BioMed (OBIO) reported that director and officer David P. Hochman bought 5,000 shares of Common Stock in an open-market transaction. This purchase was made at a weighted average price of $3.83 per share on June 1, 2026, and increased his direct holdings.

At what price did the OBIO insider buy shares in this Form 4?

The OBIO insider purchase was executed at a weighted average price of $3.83 per share. The filing notes the 5,000 shares were bought in multiple trades between $3.80 and $3.91, with detailed trade-by-trade information available upon request from the company or regulators.

How many OBIO shares does David P. Hochman hold directly after the transaction?

Following the reported transaction, David P. Hochman directly holds 1,064,029 shares of Orchestra BioMed Common Stock. This figure reflects his position after buying 5,000 shares in the open market on June 1, 2026, as disclosed in the Form 4 insider filing.

What indirect OBIO holdings are reported for David P. Hochman?

The Form 4 shows indirect OBIO holdings through several family trusts. These include 439,482 shares held by the DPH 2008 Trust and smaller positions of 3,140 and 2,000 shares in other 2008 and 2019 family trusts, reflecting shares attributed through trust ownership structures.

Was the OBIO insider transaction a buy or sell according to the Form 4?

According to the Form 4, the key OBIO insider transaction was a buy. David P. Hochman completed an open-market purchase of 5,000 Common Stock shares coded as a "P" transaction, indicating a purchase in the open market or a private transaction.